Cleerly has announced its closing of a series C financing round of $192 million (188 million euros), bringing the company's total raised to $248 million (243 million euros). The funding will allow Cleerly to expand its team and its commercial reach.
Cleerly will use the funds to invest in additional large-scale outcomes research to validate its artificial intelligence (AI) technology for evaluating coronary CT angiograms to allow physicians to identify, characterize, and qualify atherosclerosis in the walls of the heart arteries more easily.
Cleerly has more than a dozen ongoing clinical trials, including an international registry enrolling more than 100,000 patients over the next decade.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
